Exec-Edge – ExecEdge

March Biosciences CAR-T Therapy Expectations and Phase 1 Experience

March Biosciences CAR-T Therapy Expectations and Phase 1 Experience

By Daniella Parra March Bio is developing MB-105, a first-in-class autologous CD5-targeted CAR-T cell therapy for relapsed/refractory T-cell lymphoma and other CD5-positive hematologic malignancies, they said. The company said the therapy employs a proprietary CAR design that enables selective targeting of...

ReAlta Presents New Phase 2 Data in aGVHD

ReAlta Presents New Phase 2 Data in aGVHD

By Daniella Parra ReAlta Life Sciences’ Pegtarazimod demonstrated significant clinical improvement and reduction in inflammatory markers in patients with lower gastrointestinal aGvHD, the company said. Clinical MAGIC stage improvement observed for 6 of 6 patients with steroid-refractory aGvHD, with 4...

Input your search keywords and press Enter.